From iPSCs To Functional NK Cell Therapy - A Client Journey

Explore how shifting to iPSC-based allogeneic cell therapies is set to transform modern healthcare.

In this presentation, Jonas Mortensen, Chief Commercial Officer at Cellistic, leads an engaging discussion on the exciting advancements in cell therapy. This informative webinar also features insights from Suzanne Snellenberg, VP of Cell Line Development, and Anne-Sophie Lebrun, MSAT Director, who will guide you through each stage of the product journey. They will introduce the Pulse Platform, designed specifically for developing iPSC cell lines, and the Echo Platform, which facilitates differentiation into functional NK cells. Together, these innovative platforms provide an integrated approach to streamline and empower cell therapy development from beginning to end.